RXteach

The Medical Science Liaison (MSL) is an iconic role in the pharmaceutical industry and remains one of the most competitive positions for PharmDs, PhDs, MDs, and NPs looking for better work-life balance, higher pay, or broad impact. Among the many pros and cons of being an MSL, there is one aspect of the job that is unavoidable: travel. As a Senior MSL in oncology with years of experience, I've gotten quite good at traveling.

Value-based contracting has emerged as one of the most discussed strategies in pharmaceutical pricing and reimbursement to control costs and improve patient outcomes.

Author: Marta Zurawska, PhD, PharmD With so many career options available to pharmacists after graduation, the "Day in the Life" series is meant to provide you with insights into what it's like to be a pharmacist in various areas so that you can pursue what's right for you! Dr. Marta Zurawska, PhD, PharmD My name is Marta, and I hold both a PharmD and a PhD. I was born in Poland, and shortly after my parents moved to Italy, where I grew up and completed my PharmD.

Our "Day in the Life" series increases your knowledge about what career paths are available and what a typical workday entails for these professionals! With so many career options available to pharmacists after graduation, the "Day in the Life" series is meant to provide you with insights into what it's like to be a pharmacist in various areas so that you can pursue what's right for you! Dr. Kimberly Doerhoff is a Clinical Pharmacist at SSM DePaul Hospital in St. Louis, MO.

Photo by Phoenix Han / Unsplash With any antimicrobial agent, it is important to ensure the agent is (1) effective against the invasive pathogen, (2) safe for the patient, and (3) dosed correctly! Some of our antimicrobial agents are FDA-approved at fixed doses based on phase III clinical trial data, but as time goes on, more and more phase IV data emerge. Micafungin is one of those agents that have accumulated additional dosing data since its approval in 2005.

Just last month, the FDA approved orforglipron (Foundayo) – the first non-peptide glucagon-like peptide 1 (GLP-1) receptor agonist for glycemic control and weight loss.1 GLP-1 receptor agonists are generally very large molecules. Semaglutide (Ozempic, Wegovy), for example, is a sequence of 31 amino acids with a molecular weight of 4,114 g/mol.2 Orforglipron has a molecular weight of 883 g/mol, a much smaller molecule than its predecessors.

Photo by Mark Olsen / Unsplash We are back with another monthly post for our paid subscribers. We do apologize for the delay over the last two months! There is a new format for our Recaps: each article summary is located in a convenient drop-down box. Click on the down arrow to view each high-level summary! In this post, we also share a number of fun things that are more personal, interesting, and meant to create a closer community around RxTeach.

Author: Anna Rose Diel, PharmD Candidate Phantom limb pain (PLP) is a sensation of discomfort or perceived pain stemming from a part of the body that is no longer there. This sensitivity is most commonly experienced post-amputation, although the pathophysiology is not well understood. Differentiating PLP from other clinical conditions is critical before determining the treatment options available for patients (1).

Authors: Talia Holmes,  Lexus Jackson, DeYana Simpson, PharmD Candidates Editor: Kristen Lindauer, PharmD, BCPS, AAHIVP The American College of Cardiology (ACC)/ American Heart Association (AHA) published a new cholesterol guideline in March 2026 for the first time since the last updates in 2018. Join us for a brief breakdown of what changes this guideline brings to medical practice! Dyslipidemia is defined as higher-than-normal concentrations of lipids in the bloodstream.

Photo by Hans Reniers / Unsplash With advances in targeted cancer therapies and precision medicine, radiopharmaceuticals have emerged as a rapidly evolving area of the pharmaceutical industry. Radiopharmaceuticals combine radioactive isotopes with biologically targeted molecules to deliver radiation directly to tumor cells.1 This sector is attracting significant investment and strategic collaborations across major pharmaceutical companies.